



PTO/SB/08a (01-09)

Approved for use through 02/28/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 10/803,793 |
| Filing Date | March 18, 2004 |
| First Named Inventor | Erik Buntinx |
| Art Unit | 1612 |
| Examiner Name | Benjamin J. Packard |
| Attorney Docket Number | 29248/21 |

Sheet 1 of 3

U. S. PATENT DOCUMENTS

| U. S. PATENT DOCUMENTS | | | | | |
|------------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | 1 | USPTO Office Action dated 06/10/2009 in connection with U.S. Application Serial No. 10/725,965, filed 12/02/2003, Examiner Umamaheswari Ramachandran, Art Unit 1617. | | | |
| | 2 | USPTO Office Action dated 02/19/2009 in connection with U.S. Application Serial No. 10/752,423, filed 01/06/2004, Examiner Umamaheswari Ramachandran, Art Unit 1617. | | | |
| | 3 | USPTO Office Action dated 08/05/2009 in connection with U.S. Application Serial No. 10/752,423, filed 01/06/2004, Examiner Umamaheswari Ramachandran, Art Unit 1617. | | | |
| | 4 | USPTO Office Action dated 07/21/2009 in connection with U.S. Application Serial No. 10/984,683, filed 11/09/2004, Examiner Anna Pagonakis, Art Unit 1614. | | | |
| | 5 | USPTO Office Action dated 06/02/2009 in connection with U.S. Application Serial No. 10/580,962, filed 05/31/2006, Examiner Sarah Pihonak, Art Unit 1617. | | | |
| | 6 | US- 2003-0032636 A1 | 02-13-2003 | Cremers et al. | |
| | 7 | US- 6,150,353 | 11-21-2000 | Broekkamp et al. | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---|--------------------------------|--|---|----------------|
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| | 8 | WO 01/41701 A2 | 06-14-2001 | H. Lundbeck A/S | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | | | | | |
|-------|---|----|---|------------------------|---------------------|
| Sheet | 2 | of | 3 | Application Number | 10/803,793 |
| | | | | Filing Date | March 18, 2004 |
| | | | | First Named Inventor | Erik Buntinx |
| | | | | Art Unit | 1612 |
| | | | | Examiner Name | Benjamin J. Packard |
| | | | | Attorney Docket Number | 29248/21 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | 9 | PRINSSEN E P M et al., The effects of antipsychotics with 5-HT _{2C} receptor affinity in behavioral assays selective for 5-HT _{2C} receptor antagonist properties of compounds, | |
| | | European Journal of Pharmacology 388 (2000) 57-67. | |
| | 10 | MEYER U A, Overview of Enzymes of Drug Metabolism, Journal of Pharmacokinetics and Biopharmaceutics, Vol. 24, No. 5, 1996, 449-459. | |
| | 11 | VAN OEKELN D et al., Different regulation of rat 5-HT _{2A} and 5-HT _{2C} receptors in NIH 3T3 cells upon exposure to 5-HT and pipamperone, Eur. J. Pharmacology 425 (2001) 21-32. | |
| | 12 | KAHN A et al., Symptom Reduction and Suicide Risk in Patients Treated with Placebo in Antidepressant Clinical Trials, Arch Gen Psychiatry, Vol. 57, Apr 2000, 311-317. | |
| | 13 | MONTGOMERY S A et al., Escitalopram versus venlafaxine XR in the treatment of depression, International Clinical Psychopharmacology 2006, 21:297-309. | |
| | 14 | MOORE N et al., Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder, International Clinical Psychopharmacology 2005, 20:131-137. | |
| | 15 | STEIN D J et al., Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders, J Clin Psychiatry, 1997, 58(3):119-122. | |
| | 16 | ALBERT U et al., Management of treatment resistant obsessive-compulsive disorder. Algorithms for Pharmacotherapy, Panminerva Med, 2002, 44(2):83-91. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 10/803,793 |
| Filing Date | March 18, 2004 |
| First Named Inventor | Erik Buntinx |
| Art Unit | 1612 |
| Examiner Name | Benjamin J. Packard |
| Attorney Docket Number | 29248/21 |

| | | | |
|-------|---|----|---|
| Sheet | 3 | of | 3 |
|-------|---|----|---|

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | 17 | MOHR N et al., Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorders, Int Clin Psychopharmacol, 2002, 17(1):37-40. | |
| | 18 | SILVER H, Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia," 2003, Int Clin Psychopharmacol, 18(6):305-313. | |
| | 19 | PEREMANS K et al., Evaluation of serotonin-2A receptor occupancy with 123I-5-I-R91150 and single-photon emission tomography before and after low-dose pipamperone | |
| | | administration in the canine brain, Nucl Med Commun, 2008 Aug;29 (8):724-9. | |
| | 20 | BUNTINX E et al., PreClinical and Clinical Evidence for the Efficacy of Pipamperone in Augmenting the Antidepressant Effects of the SSRI Citalopram, | |
| | | presented at the XXVI Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress 13-17 July 2008, Munich, Germany, 1 page. | |
| | 21 | JANSSEN-CILAB B.V instructions for Dipiperon tablets 40 mg. and Dipiperon drops 40 mg/ml. | |
| | 22 | MARSH L. Neuropsychiatric aspects of Parkinson's Disease. Psychosomatics 41:15-23, 2000. | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.